imvigor 210 cohort first-line atezolizumab cisplatin ineligible metastatic urothelial队列一线Atezolizumab中顺铂符号转移性尿路上皮癌.pptx

下载文档

0
0
约6.15千字
约 11页
2025-03-17 发布于北京
举报
版权申诉
保障服务

imvigor 210 cohort first-line atezolizumab cisplatin ineligible metastatic urothelial队列一线Atezolizumab中顺铂符号转移性尿路上皮癌.pptx

1、本文档共11页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

CCOIndependentConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016IMvigor210(Cohort1):First-lineAtezolizumabinCisplatin-IneligibleMetastaticUrothelialCarcinoma*CCOisanindependentmedicaleducationcompanythatprovidesstate-of-the-artmedicalinformationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,Incyte,Merck,andTaihoPharmaceuticals.

IMvigor210(Cohort1):BackgroundCisplatintheisfirst-linestandardofcareformetastaticurothelialcarcinomaMostptsarecisplatinineligibleduetopoorperformancestatus,impairedrenalfunction,orcomorbidities[1]Non-cisplatin–basedregimensassociatedwithshortresponseduration,lackofsurvivalbenefit,highdiscontinuationrate[2]Atezolizumab:engineeredmAbtargetingPD-L1immunecheckpointActive,welltoleratedintreatment-experiencedmUC[3]CurrentlyFDAapprovedonlyincisplatin-treatedptsCohort1oftheIMvigor210studyevaluatedsafety,efficacyofatezolizumabasfirst-linetherapyinuntreated,cisplatin-ineligiblemUCpts[4]1.GalaskyMD.ECC2015.Abstract2624.2.DeSantisM,etal.JClinOncol.2012;30:191-199.3.RosenbergJE,etal.Lancet.2016;387:1909-1920.

4.BalarAV,etal.ASCO2016.AbstractLBA4500.Slidecredit:

Single-armphaseIIstudywith2cohorts[1]IMvigor210:StudyDesignPtswithinoperableadvancedormetastaticUC,predominantlyTCChistology,evaluabletumortissuefor

PD-L1testing(N=429)Cohort1:(n=119)[2]previouslyuntreated,cisplatinineligible*Cohort2:(n=310)[3]priorplatinumtreatmentSlidecredit:Atezolizumab1200mgIVQ3WuntilPDAtezolizumab1200mgIVQ3Wuntillossofbenefit1.ClinicalTrials.gov.NC2.BalarAV,etal.ASCO2016.AbstractLBA4500.3.DreicerR,etal.ASCO2016.Abstract4515.Cohort1studyPrimaryendpoint:confirmedORRb